Product Images Gabapentin

This description is for Gabapentin Capsules, USP, which are available in a pack of 100 capsules with a strength of 400 mg. Each capsule is a unit dose capsule and the pack has a total of 10x10 capsules. The manufacturer is not mentioned, but there is a reference to a company called McKesson Corporation db Sy Packaging. The capsule bottle must be stored at Controlled Room Temperature 20°C to 25°C. The other text appears to be random characters and is not relevant.*

Gabapentin Capsules, USP is a medication that comes in a package of 100 unit dose capsules, each containing 300mg of Gabapentin USP. It is intended to be prescribed by a healthcare professional and stored at room temperature. The medication guide is provided to each patient who takes it. The manufacturing company is Hexion Corporation, doing business as Sy Packaging located in Tennessee.*

Gabapentin Capsules, USP, 400 mg, is a prescription medication used to treat nerve-related pain caused by shingles and epilepsy. Each package contains 100 (10 x10) unit dose capsules, and must be dispensed according to the enclosed education guide. The medication must be stored at controlled room temperature. The drug is manufactured by Akom Laboratories L. in India and distributed in the US by the pharmaceutical company Recodo Laboratories, L.*

This appears to be a chart related to a study or experiment involving pain relief. The chart shows two periods of time, a four-week dose titration period and a four-week fixed dose period, with the mean pain score rated at 10. The chart also includes a comparison between a placebo and Gabapentin at 3600mg/day. Baseline 1 is also mentioned. It is likely that this chart represents data analysis of pain management medication.*

This is a table that shows the mean pain score of participants in a clinical trial. It has four different treatment groups: placebo, gabapentin 1800 mg/day, gabapentin 2400 mg/day, and a fixed dose period. The table displays two different periods: a dose titration period and a fixed dose period. The baseline measurement of pain score is also included.*

The text provides a figure showing the proportion of responders in controlled PHN studies based on pain score reduction. The figure indicates different percentage values between 10% and 100%. The study shows that up to 29% of patients in the study respond positively to interventions aimed at reducing pain scores. The text also mentions different GBP values associated with different interventions, including GBP 3600, GBP 1800, and GBP 2400. The text does not provide sufficient information to determine the exact nature of the study or the interventions used.*